Drug profile · INN
tebentafusp-tebn
KIMMTRAK
tebentafusp-tebn (KIMMTRAK) is a melanocyte protein pmel binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — tebentafusp-tebn
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tebentafusp-tebn (KIMMTRAK) is a melanocyte protein pmel binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Melanocyte protein PMEL binding agent
Primary target: Melanocyte protein PMEL
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tebentafusp-tebn?
tebentafusp-tebn (KIMMTRAK) is a melanocyte protein pmel binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tebentafusp-tebn?
KIMMTRAK is a marketed brand name for tebentafusp-tebn. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tebentafusp-tebn?
tebentafusp-tebn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.